ATE287710T1 - Verfahren zum modulieren der mikrozirkulation - Google Patents
Verfahren zum modulieren der mikrozirkulationInfo
- Publication number
- ATE287710T1 ATE287710T1 AT96919782T AT96919782T ATE287710T1 AT E287710 T1 ATE287710 T1 AT E287710T1 AT 96919782 T AT96919782 T AT 96919782T AT 96919782 T AT96919782 T AT 96919782T AT E287710 T1 ATE287710 T1 AT E287710T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- arginine
- medicament
- precursor
- sec
- Prior art date
Links
- 230000004089 microcirculation Effects 0.000 title 1
- 206010058558 Hypoperfusion Diseases 0.000 abstract 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 2
- 229930064664 L-arginine Natural products 0.000 abstract 2
- 235000014852 L-arginine Nutrition 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 235000016709 nutrition Nutrition 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 238000002283 elective surgery Methods 0.000 abstract 1
- 239000002840 nitric oxide donor Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Photolithography (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9510037.6A GB9510037D0 (en) | 1995-05-18 | 1995-05-18 | Improvements in or relating to organic compounds |
| PCT/EP1996/002124 WO1996036327A1 (en) | 1995-05-18 | 1996-05-17 | Method of modulating microcirculation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE287710T1 true ATE287710T1 (de) | 2005-02-15 |
Family
ID=10774643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96919782T ATE287710T1 (de) | 1995-05-18 | 1996-05-17 | Verfahren zum modulieren der mikrozirkulation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5902829A (de) |
| EP (1) | EP0914110B1 (de) |
| JP (1) | JP3908785B2 (de) |
| AT (1) | ATE287710T1 (de) |
| CA (1) | CA2215692C (de) |
| DE (1) | DE69634269T2 (de) |
| ES (1) | ES2236736T3 (de) |
| GB (1) | GB9510037D0 (de) |
| PT (1) | PT914110E (de) |
| WO (1) | WO1996036327A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239172B1 (en) * | 1997-04-10 | 2001-05-29 | Nitrosystems, Inc. | Formulations for treating disease and methods of using same |
| CA2210856A1 (en) * | 1995-01-18 | 1996-07-25 | Taisho Pharmaceutical Co., Ltd. | Dermatitis-curing agent |
| US6117872A (en) * | 1998-06-23 | 2000-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity |
| EP1126831A4 (de) * | 1998-10-06 | 2004-10-06 | Diamedica Inc | Methoden zur behandlung der insulinresistenz durch stickstoffmonoxyd der leber |
| US20040151785A1 (en) * | 1998-10-06 | 2004-08-05 | Diamedica Inc. | Method for treating insulin resistance through hepatic nitric oxide |
| AU784752B2 (en) * | 1999-10-18 | 2006-06-08 | Northern Innovations Holding Corp. | Food supplement for increasing lean mass and strength |
| US6784209B1 (en) * | 1999-10-18 | 2004-08-31 | Muscletech Research And Development Inc. | Food supplement for increasing lean mass and strength |
| US6423349B1 (en) | 2000-08-24 | 2002-07-23 | Baxter International, Inc. | Therapeutic nutrient composition for pre and post elective surgery |
| PT1195178E (pt) * | 2000-10-06 | 2006-10-31 | Dmg Italia Srl | Preparacao imunotrofica para o tratamento da hipertrofia adenoamigdalar. |
| EP1372641A4 (de) * | 2001-03-05 | 2004-08-25 | Stephen P Ernest | Enterale formulierung |
| NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| DE10257360A1 (de) * | 2002-12-09 | 2004-07-08 | Fresenius Kabi Deutschland Gmbh | Gastro-intestinal verabreichbare Formulierung und deren Verwendung |
| EP1591118A1 (de) | 2004-04-27 | 2005-11-02 | Nutri-Fit GmbH & Co. KG | Verwendung von Melatonin zur Vorbeugung von postoperativen Komplikationen |
| US8445536B2 (en) * | 2005-03-31 | 2013-05-21 | Ajinomoto Co., Inc. | Arginine-containing compositions and methods for increasing blood flow using same |
| AU2011221341B2 (en) * | 2005-08-26 | 2013-11-28 | Nestec S.A. | Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis in ischemia or after ischemic episode in the brain |
| US20070053955A1 (en) * | 2005-08-26 | 2007-03-08 | Nestec S.A. | Compositions and methods for improving cellular survival and reducing apoptosis after ischemic episode in the brain |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| US20130323222A1 (en) | 2012-06-04 | 2013-12-05 | Matthew Charles | Human tissue kallikrein 1 glycosylation isoforms |
| RU2541184C1 (ru) * | 2013-09-23 | 2015-02-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне комбинацией рекомбинантного эритропоэтина и розувастатина |
| AU2018230478B2 (en) | 2017-03-09 | 2025-01-23 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE192037T1 (de) * | 1989-12-29 | 2000-05-15 | Braun Medical Inc | Verwendung von arginin als immunstimulator |
| EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| JPH04282313A (ja) * | 1991-03-11 | 1992-10-07 | Ajinomoto Co Inc | 血圧降下剤 |
| JPH04330011A (ja) * | 1991-04-30 | 1992-11-18 | Morishita Roussel Kk | 末梢動脈閉塞症改善剤 |
| JPH0638708A (ja) * | 1992-05-15 | 1994-02-15 | Earth Chem Corp Ltd | ナトリウム吸収阻害剤、ナトリウム吸収阻害剤を含有する高血圧予防食品、及び高血圧治療剤 |
| US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
| US5436270A (en) * | 1993-04-07 | 1995-07-25 | National Science Council | Method for protecting against endotoxin-induced shock |
| US5656608B1 (en) * | 1995-02-23 | 2000-09-26 | Novartis Nutrition Ltd | Amino acid compositions and methods of treatment using same |
-
1995
- 1995-05-18 GB GBGB9510037.6A patent/GB9510037D0/en active Pending
-
1996
- 1996-05-17 EP EP96919782A patent/EP0914110B1/de not_active Expired - Lifetime
- 1996-05-17 JP JP53456396A patent/JP3908785B2/ja not_active Expired - Lifetime
- 1996-05-17 PT PT96919782T patent/PT914110E/pt unknown
- 1996-05-17 AT AT96919782T patent/ATE287710T1/de active
- 1996-05-17 CA CA002215692A patent/CA2215692C/en not_active Expired - Lifetime
- 1996-05-17 ES ES96919782T patent/ES2236736T3/es not_active Expired - Lifetime
- 1996-05-17 US US08/952,806 patent/US5902829A/en not_active Expired - Lifetime
- 1996-05-17 WO PCT/EP1996/002124 patent/WO1996036327A1/en not_active Ceased
- 1996-05-17 DE DE69634269T patent/DE69634269T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69634269T2 (de) | 2006-03-30 |
| CA2215692A1 (en) | 1996-11-21 |
| DE69634269D1 (de) | 2005-03-03 |
| JP3908785B2 (ja) | 2007-04-25 |
| EP0914110A1 (de) | 1999-05-12 |
| US5902829A (en) | 1999-05-11 |
| JPH11505541A (ja) | 1999-05-21 |
| EP0914110B1 (de) | 2005-01-26 |
| GB9510037D0 (en) | 1995-07-12 |
| PT914110E (pt) | 2005-05-31 |
| WO1996036327A1 (en) | 1996-11-21 |
| MX9708873A (es) | 1998-06-30 |
| CA2215692C (en) | 2007-09-25 |
| ES2236736T3 (es) | 2005-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69634269D1 (de) | Verfahren zum modulieren der mikrozirkulation | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| DE68919358D1 (de) | Zusammensetzung zur behandlung der schizophrenie. | |
| ATE173148T1 (de) | Kombinationspräparat zur förderung des haarwachstums und ggf. des haut- und nagelwachstums sowie zur verhinderung bzw. zur beseitigung von haarausfall | |
| LU90956I2 (fr) | Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique | |
| NO964864L (no) | Orale, flytende alendronatpreparater | |
| SE9500422D0 (sv) | New oral pharmaceutical dosage forms | |
| ATE146677T1 (de) | Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit | |
| ATE233091T1 (de) | Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen | |
| DE69634357D1 (de) | Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten | |
| CA2148194A1 (en) | Cyclopeptides of the formula i | |
| DE69800859D1 (de) | Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen | |
| DE69522702D1 (de) | Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält | |
| ATE143947T1 (de) | N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten | |
| DK0866711T3 (da) | Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö | |
| NO923198L (no) | Terapeutiske midler | |
| BR9809127A (pt) | Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente | |
| PT98764A (pt) | Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos | |
| KR940003550A (ko) | 노인성 치매 예방 및 치료방법 | |
| CZ176395A3 (en) | The use of riluzol for preparing medicaments acceptable as antidotes against harmful effects of irradiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0914110 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |